Evidence map›Paper›PMID 39807698›Full record

ArticleEuropean journal of neurology2025

Lyme neuroborreliosis in Japan: Borrelia burgdorferi sensu lato as a cause of meningitis of previously undetermined etiology in hospitalized patients outside of the island of Hokkaido, 2010-2021.

Masayuki Ohira, Ai Takano, Kentaro Yoshi, Akira Arai, Yashuhiro Aso, Rikiya Furutani, Tadanori Hamano, Ikuko Takahashi-Iwata, Chikako Kaneko, Tohru Matsuura and 18 more

Abstract read
In one paragraph

Article in European journal of neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

Masayuki OhiraDepartment of Clinical Laboratory and Internal Medicine, National Center of Neurology and Psychiatry, Tokyo, Japan.
Ai TakanoDepartment of Veterinary Medicine, Joint Faculty of Veterinary Medicine, Yamaguchi University, Yamaguchi, Japan.ORCID 0000-0002-5919-3738
Kentaro YoshiNational Research Center for the Control and Prevention of Infectious Diseases, Nagasaki University, Nagasaki, Japan.
Akira AraiDepartment of Neurology, Aomori Prefectural Central Hospital, Aomori, Japan.
Yashuhiro AsoDepartment of Neurology, Oita Prefectural Hospital, Oita, Japan.
Rikiya FurutaniDepartment of Neurology, National Hospital Organization, Shinshu Ueda General Hospital, Nagano, Japan.
Tadanori HamanoDepartment of Neurology, University of Fukui Hospital, Fukui, Japan.
Ikuko Takahashi-IwataDepartment of Neurology, Hokkaido University Hospital, Hokkaido, Japan.
Chikako KanekoDepartment of Neurology, Southern Tohoku General Hospital, Fukushima, Japan.
Tohru MatsuuraDivision of Neurology, Jichi Medical University, Tochigi, Japan.
Norihisa MaedaDepartment of Neurology, National Hospital Organization Beppu Medical Center, Oita, Japan.
Hideto NakajimaDepartment of Neurology, Nihon University Itabashi Hospital, Tokyo, Japan.ORCID 0000-0002-2154-9196
Katsuro ShindoDepartment of Neurology, Kurashiki Central Hospital, Okayama, Japan.
Toshihiko SuenagaDepartment of Neurology, Tenri Hospital, Nara, Japan.
Kazuma SugieDepartment of Neurology, Nara Medical University Hospital, Nara, Japan.
Yasuhiro SuzukiDepartment of Neurology, National Hospital Organization Asahikawa Medical Center, Hokkaido, Japan.
Toru YamashitaDepartment of Neurology, Okayama University Hospital, Okayama, Japan.
Frederick J AnguloVaccines and Antivirals Medical Affairs, Pfizer Vaccines, Collegeville, Pennsylvania, USA.ORCID 0000-0002-3120-7704
Juanita EdwardsVaccines and Antivirals Medical Affairs, Pfizer Vaccines, Collegeville, Pennsylvania, USA.
Cody Matthew BenderVaccines and Antivirals Medical Affairs, Pfizer Vaccines, Collegeville, Pennsylvania, USA.
Lisa R HarperVaccines and Antivirals Medical Affairs, Pfizer Vaccines, Collegeville, Pennsylvania, USA.
Yoshikazu NakayamaVaccines Medical Affairs, Pfizer Japan Inc, Tokyo, Japan.
Shuhei ItoVaccines Medical Affairs, Pfizer Japan Inc, Tokyo, Japan.
Andreas PilzVaccines and Antivirals Medical Affairs, Pfizer Vaccines, Vienna, Austria.
James H StarkVaccines and Antivirals Medical Affairs, Pfizer Vaccines, Cambridge, Massachusetts, USA.
Jennifer C MoïsiVaccines and Antivirals Medical Affairs, Pfizer Vaccines, Paris, France.
Hidehiro MizusawaDepartment of Neurology, National Center of Neurology and Psychiatry, Tokyo, Japan.
Masaki TakaoDepartment of Clinical Laboratory and Internal Medicine, National Center of Neurology and Psychiatry, Tokyo, Japan.

Funding

Pfizer
6 · The paper itself

Abstract

background and purposeClinical manifestations of Lyme borreliosis (LB), caused by Borrelia burgdorferi sensu lato (Bbsl), include erythema migrans, Lyme neuroborreliosis (LNB), carditis, and arthritis. LB is a notifiable disease in Japan with <30 surveillance-reported LB cases annually, predominately from Hokkaido Prefecture. However, LB, including LNB, may be under-diagnosed in Japan since diagnostic tests are not readily available. We sought to determine if LNB could be a cause of previously undiagnosed encephalitis or meningitis in Japan.

methodsInvestigators at 15 hospitals in 10 prefectures throughout Japan retrieved serum and/or cerebrospinal fluid (CSF) samples collected in 2010-2021 from 517 patients hospitalized with encephalitis or meningitis which had an etiology that had not been determined. Samples were tested for Bbsl-specific antibodies using ELISA and Western blot tests. In alignment with the European Union LNB case definition, a confirmed LNB case had CSF pleocytosis and intrathecal production of Bbsl-specific antibodies and a probable LNB case had a CSF sample with pleocytosis and Bbsl-specific antibodies.

resultsLNB was identified in three hospitalized patients with meningitis of previously undetermined etiology: a male resident of Aomori Prefecture was a confirmed LNB case, and two female residents of Oita Prefecture were probable LNB cases. None of the patients with confirmed or probable LNB had traveled in the month prior to symptom onset and none had samples previously tested for LB.

conclusionThe identification of previously undiagnosed LNB cases indicates a need for enhanced disease awareness in Japan, particularly beyond Hokkaido Island, and more readily available LB diagnostic testing.

Indexed as

Borrelia burgdorferi GroupLyme NeuroborreliosisMeningitisAdultAgedAged, 80 and overAntibodies, BacterialFemaleHospitalizationHumansJapanMaleMiddle AgedAntibodies, Bacterialdisease burdenepidemiologyLyme neuroborreliosismeningitistick‐borne disease

Identifiers

PMID39807698
PMCPMC11729742

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.